Association of preoperative inflammation-based prognostic score with survival in patients undergoing salvage esophagectomy.


Journal

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
ISSN: 1442-2050
Titre abrégé: Dis Esophagus
Pays: United States
ID NLM: 8809160

Informations de publication

Date de publication:
01 Apr 2019
Historique:
pubmed: 12 12 2018
medline: 26 11 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Salvage esophagectomy (SALV) is potentially beneficial for patients with residual or relapsed esophageal carcinoma after definitive chemoradiotherapy (dCRT), although preoperatively identifying good candidates for SALV remains difficult. We investigated the prognostic impacts of inflammatory and nutritional status in patients undergoing SALV after dCRT. Forty-seven SALV patients were retrospectively reviewed, of whom 46 (98%) had squamous cell carcinoma and 1 (2%) adenocarcinoma. Possible prognostic factors included patients' demographic data, physical status, blood chemistry profiles, and clinical/pathological tumor features. The Glasgow prognostic score (GPS) was derived from preoperative C-reactive protein (CRP) and albumin values. Thirty (64%), 11 (23%), and 6 (13%) patients were classified into the GPS 0, 1, and 2, respectively, groups. None of the possible prognostic factors showed significant correlations with GPS. Patients with GPS 0 had better outcomes than those with GPS 1 or GPS 2 (Median survivals: 37.8, 15.9, and 5.1 months, respectively, P < 0.001). In the multivariable Cox proportional hazards model, GPS 1 (HR 5.62, 95% CI 1.94-16.4, P = 0.002), GPS 2 (HR 9.10, 95% CI 2.60-31.8, P < 0.001), R1/2 resection (HR 16.3, 95% CI 3.62-86.7, P < 0.001) and incomplete response to dCRT (HR 3.53, 95% CI 1.12-12.5, P = 0.03) were all independent risk factors for a poor outcome. Preoperative GPS is potentially useful for predicting outcomes in esophageal cancer patients undergoing SALV.

Identifiants

pubmed: 30535140
pii: 5060212
doi: 10.1093/dote/doy066
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
C-Reactive Protein 9007-41-4

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus.

Auteurs

K Sugawara (K)

Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo.

K Mori (K)

Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo.
Department of Gastrointestinal Surgery, Mitsui Memorial Hospital, Tokyo, Japan.

K Yagi (K)

Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo.

S Aikou (S)

Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo.

Y Uemura (Y)

Biostatistics Division, Clinical Research Support Center, Graduate School of Medicine, the University of Tokyo.

H Yamashita (H)

Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo.

Y Seto (Y)

Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH